269 related articles for article (PubMed ID: 33029256)
21. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
22. L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma.
Tsutsumi S; Morohashi S; Kudo Y; Akasaka H; Ogasawara H; Ono M; Takasugi K; Ishido K; Hakamada K; Kijima H
J Surg Oncol; 2011 Jun; 103(7):669-73. PubMed ID: 21360711
[TBL] [Abstract][Full Text] [Related]
23. Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma.
Pozios I; Knösel T; Zhao Y; Assmann G; Pozios I; Müller MH; Bruns CJ; Kreis ME; Seeliger H
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1887-1897. PubMed ID: 30046904
[TBL] [Abstract][Full Text] [Related]
24. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
Endo Y; Kitago M; Aiura K; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Nakano Y; Itano O; Fukada J; Masugi Y; Kitagawa Y
World J Surg Oncol; 2019 Aug; 17(1):145. PubMed ID: 31420046
[TBL] [Abstract][Full Text] [Related]
26. Annexin A2 and CD105 expression in pancreatic ductal adenocarcinoma is associated with tumor recurrence and prognosis.
Huang YK; Liu H; Wang XZ; Zhu S
Asian Pac J Cancer Prev; 2014; 15(22):9921-6. PubMed ID: 25520129
[TBL] [Abstract][Full Text] [Related]
27. Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer.
Chikamoto A; Inoue R; Komohara Y; Sakamaki K; Hashimoto D; Shiraishi S; Takamori H; Yamashita YI; Yoshida N; Yamanaka T; Yamashita Y; Baba H
Ann Surg Oncol; 2017 Jul; 24(7):2040-2046. PubMed ID: 28180987
[TBL] [Abstract][Full Text] [Related]
28. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
[TBL] [Abstract][Full Text] [Related]
29. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.
Aziz MH; Sideras K; Aziz NA; Mauff K; Haen R; Roos D; Saida L; Suker M; van der Harst E; Mieog JS; Bonsing BA; Klaver Y; Koerkamp BG; van Eijck CH
Ann Surg; 2019 Jul; 270(1):139-146. PubMed ID: 29334554
[TBL] [Abstract][Full Text] [Related]
30. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients.
Park JY; King J; Reber H; Joe Hines O; Mederos MA; Wang HL; Dawson D; Wainberg Z; Donahue T; Girgis M
J Surg Oncol; 2021 Feb; 123(2):389-398. PubMed ID: 33146409
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of adjacent organ resection in patients with left-sided pancreatic ductal adenocarcinoma following distal pancreatectomy.
Song KB; Kwon J; Kim YW; Hwang DW; Lee JH; Hong S; Lee JW; Hwang K; Yoo D; Kim SC
J Hepatobiliary Pancreat Sci; 2019 Jun; 26(6):227-234. PubMed ID: 30980486
[TBL] [Abstract][Full Text] [Related]
32. Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-institutional Retrospective Study.
Murakawa M; Yamamoto N; Kamioka Y; Kamiya M; Kobayashi S; Ueno M; Morimoto M; Atsumi Y; Aoyama T; Tamagawa H; Yukawa N; Rino Y; Masuda M; Morinaga S
In Vivo; 2020; 34(1):347-353. PubMed ID: 31882498
[TBL] [Abstract][Full Text] [Related]
33. Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes.
Gilabert M; Turrini O; Ewald J; Moureau-Zabotto L; Poizat F; Raoul JL; Delpero JR
Surg Oncol; 2018 Dec; 27(4):619-624. PubMed ID: 30449481
[TBL] [Abstract][Full Text] [Related]
34. Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma.
Jin W; Xu HX; Zhang SR; Li H; Wang WQ; Gao HL; Wu CT; Xu JZ; Qi ZH; Li S; Ni QX; Liu L; Yu XJ
Ann Surg Oncol; 2019 Feb; 26(2):635-643. PubMed ID: 30374923
[TBL] [Abstract][Full Text] [Related]
35. Expression and Prognostic Value of Small Mothers Against Decapentaplegic 7, Matrix Metalloproteinase 2, and Matrix Metalloproteinase 9 in Resectable Pancreatic Ductal Adenocarcinoma.
Zhou L; Lu J; Liang ZY; Zhou WX; Wang YZ; Jiang BL; You L; Guo JC
Pancreas; 2021 Sep; 50(8):1195-1201. PubMed ID: 34714284
[TBL] [Abstract][Full Text] [Related]
36. Effect of CD74 on the prognosis of patients with resectable pancreatic cancer.
Zhang JF; Hua R; Liu DJ; Liu W; Huo YM; Sun YW
Hepatobiliary Pancreat Dis Int; 2014 Feb; 13(1):81-6. PubMed ID: 24463084
[TBL] [Abstract][Full Text] [Related]
37. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma.
Brunner M; Maier K; Rümmele P; Jacobsen A; Merkel S; Benard A; Krautz C; Kersting S; Grützmann R; Weber GF
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150869
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma.
Pergolini I; Crippa S; Pagnanelli M; Belfiori G; Pucci A; Partelli S; Rubini C; Castelli P; Zamboni G; Falconi M
BJS Open; 2019 Oct; 3(5):646-655. PubMed ID: 31592095
[TBL] [Abstract][Full Text] [Related]
40. Anterior gradient 2 and mucin 4 expression mirrors tumor cell differentiation in pancreatic adenocarcinomas, but aberrant anterior gradient 2 expression predicts worse patient outcome in poorly differentiated tumors.
Brychtova V; Hermanova M; Karasek P; Lenz J; Selingerova I; Vojtesek B; Kala Z; Hrstka R
Pancreas; 2014 Jan; 43(1):75-81. PubMed ID: 24177142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
